PriceTargets.com logo

Akari Therapeutics - AKTX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.30
  • Forecasted Upside: 870.59%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.34 As of 12/4/2025 05:00 PM ET
+0 (0.00%)

This chart shows the closing price for AKTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Akari Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKTX

Analyst Price Target is $3.30
▲ +870.59% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Akari Therapeutics in the last 3 months. The average price target is $3.30, with a high forecast of $5.00 and a low forecast of $1.60. The average price target represents a 870.59% upside from the last price of $0.34.

This chart shows the closing price for AKTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Akari Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/9/2025HC WainwrightReiterated RatingBuy ➝ Buy$1.60
7/18/2025Maxim GroupInitiated CoverageBuy$5.00
12/5/2022HC WainwrightInitiated CoverageBuy$30.00
11/1/2022Alliance Global PartnersInitiated CoverageBuy$80.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Akari Therapeutics logo
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.
Read More

Today's Range

Now: $0.34
Low: $0.32
High: $0.36

50 Day Range

MA: $0.70
Low: $0.34
High: $1.05

52 Week Range

Now: $0.34
Low: $0.29
High: $1.73

Volume

507,983 shs

Average Volume

1,003,204 shs

Market Capitalization

$12.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Akari Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Akari Therapeutics in the last year: HC Wainwright, Maxim Group, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for AKTX.

What is the current price target for Akari Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Akari Therapeutics in the last year. Their average twelve-month price target is $3.30, suggesting a possible upside of 840.2%. Maxim Group has the highest price target set, predicting AKTX will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $1.60 for Akari Therapeutics in the next year.
View the latest price targets for AKTX.

What is the current consensus analyst rating for Akari Therapeutics?

Akari Therapeutics currently has 1 sell rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AKTX, but not buy more shares or sell existing shares.
View the latest ratings for AKTX.

What other companies compete with Akari Therapeutics?

Other companies that are similar to Akari Therapeutics include Grace Therapeutics, Synaptogenix, Cue Biopharma, Kezar Life Sciences and LAVA Therapeutics. Learn More about companies similar to Akari Therapeutics.

How do I contact Akari Therapeutics' investor relations team?

Akari Therapeutics' physical mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company's listed phone number is 442080040261 and its investor relations email address is [email protected]. The official website for Akari Therapeutics is www.akaritx.com. Learn More about contacing Akari Therapeutics investor relations.